Physician profile
Holly Poland
NPI 1346754793
$557.60
in general payments reported to CMS, 2019-2025
11 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $124 · 2022: $66.03 · 2023: $49.43 · 2024: $120 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $367.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $306.69 | 2021-2025 | Belbuca, Xtampza |
| Boston Scientific Corporation | $48.27 | 2022-2024 | |
| Ibsa Pharma INC. | $37.09 | 2025 | Licart, Tirosint, Flector |
| Scilex Pharmaceuticals INC. | $30.72 | 2022 | |
| Indivior INC. | $30.28 | 2025 | Sublocade |
| Averitas Pharma INC. | $23.48 | 2025 | Qutenza |
| Redhill Biopharma INC. | $20.02 | 2021 | |
| Medtronic, INC. | $17.30 | 2024 | Intellis Adaptivestim |
| Piramal Critical Care | $15.97 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.62 | 2023 | Relistor |
| Grt US Holding, INC. | $13.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Poland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.